Raptiva

VOLUNTARY U.S. MARKET WITHDRAWAL OF RAPTIVA® (efalizumab) 

On April 8, 2009, the FDA announced that Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), is voluntarily withdrawing that product from the U. S. market.  This action is being taken because of the potential risk to patients of developing a rare and potentially fatal brain infection, progressive multifocal leukoencephalopathy (PML).  PML is an infection caused by the “JC” virus which can affect the central nervous system.  It can cause death or severe disability.  The phase-out withdrawal is to be completed by June 8, 2009.  Raptiva will no longer be available in the United States.

Symptoms of PML could include:

Weakness
Paralysis
Vision Loss
Impaired Speech, Slurring of Words
Cognitive Deterioration
Death

 
If you or a loved one has been injured by Raptiva, please give our firm a call at 800-531-9191 or send us an email at  info@wardblacklaw.com. We’ll be glad to help you.

Back to Defective Products & Medical Devices

Back to What We Do